Beigene Ltd
ONC299.940USD
-5.800-1.90%
Cierre 07/30, 16:00（ET）Cotizaciones retrasadas 15 min
29.72BCap. mercado
PérdidaP/E TTM
Más Datos de BeOne Medicines AG Compañía
BeOne Medicines Ltd., formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Información de la empresa
Símbolo de cotizaciónONC
Nombre de la empresaBeOne Medicines AG
Fecha de salida a bolsa- -
Fundada en2025
Director ejecutivoMr. John Victor Oyler
Número de empleados11000
Tipo de seguridadOrdinary Share
Fin del año fiscal- -
Direcciónc/o BeOne Medicines I GmbH
CiudadBASEL
Bolsa de valoresThe Toronto Stock Exchange
PaísSwitzerland
Código postal4051
Teléfono41616851900
Sitio Web
Símbolo de cotizaciónONC
Fecha de salida a bolsa- -
Fundada en2025
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
-33.42%
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
-33.42%
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
Other
-1.03B
-92.23%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
567.21M
50.77%
China
399.59M
35.76%
Europe
118.55M
10.61%
ROW
31.92M
2.86%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
Other
-1.03B
-92.23%
Estadísticas de accionistas
Actualizado: mié., 23 de jul
Actualizado: mié., 23 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Amgen Inc
17.28%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.64%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.12%
Accionistas
Accionistas
Proporción
Amgen Inc
17.28%
Baker Bros. Advisors LP
8.03%
Capital International Investors
4.64%
PRIMECAP Management Company
4.61%
Baillie Gifford & Co.
3.31%
Other
62.12%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
21.83%
Corporation
17.29%
Hedge Fund
10.90%
Investment Advisor/Hedge Fund
4.72%
Sovereign Wealth Fund
1.32%
Research Firm
0.89%
Pension Fund
0.21%
Bank and Trust
0.11%
Family Office
0.02%
Other
42.71%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
552
64.44M
58.80%
+1.87M
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Amgen Inc
18.94M
17.28%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.03%
--
--
Mar 31, 2025
Capital International Investors
5.09M
4.64%
-1.02M
-16.72%
Mar 31, 2025
PRIMECAP Management Company
5.06M
4.61%
-43.40K
-0.85%
Mar 31, 2025
Baillie Gifford & Co.
3.63M
3.31%
-40.48K
-1.10%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.36M
3.07%
+1.58M
+88.38%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.41M
1.29%
-80.54K
-5.39%
Mar 31, 2025
T. Rowe Price International Ltd
1.30M
1.19%
-143.22K
-9.92%
Mar 31, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
May 09, 2025
Temasek Holdings Pte. Ltd.
993.75K
0.91%
-531.58K
-34.85%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
First Trust NYSE Arca Biotechnology Index Fund
3.35%
Tema Oncology ETF
2.71%
VanEck Biotech ETF
2.17%
Global X Aging Population ETF
1.94%
Virtus LifeSci Biotech Products ETF
1.74%
iShares Health Innovation Active ETF
1.43%
iShares Biotechnology ETF
1.42%
Invesco Nasdaq Biotechnology ETF
1.15%
ProShares Ultra Nasdaq Biotechnology
1.14%
National Security Emerging Markets Index ETF
0.68%
Ver más
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.35%
Tema Oncology ETF
Proporción2.71%
VanEck Biotech ETF
Proporción2.17%
Global X Aging Population ETF
Proporción1.94%
Virtus LifeSci Biotech Products ETF
Proporción1.74%
iShares Health Innovation Active ETF
Proporción1.43%
iShares Biotechnology ETF
Proporción1.42%
Invesco Nasdaq Biotechnology ETF
Proporción1.15%
ProShares Ultra Nasdaq Biotechnology
Proporción1.14%
National Security Emerging Markets Index ETF
Proporción0.68%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
